Pronto disponible para inscripción
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

Invincible-3 Trial (Recurrent, Metastatic Soft Tissue Sarcoma) - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to find the most effective, safe dose of an experimental drug called INT230-6 (the study drug) in people with recurrent, inoperable, or metastatic soft tissue sarcomas (STS). We also want to know how well it works compared to the usual treatments for people with this diagnosis.

¿Cuál es la Condición que se está estudiando?

Recurrent, Inoperable, or Metastatic Soft Tissue Sarcomas (STS)

¿Quién puede participar en el Estudio?

Adults ages 18+ who:

  • Are diagnosed with unresectable, locally advanced, or metastatic STS of one of the following subtypes: liposarcoma (dedifferentiated, myxoid, round cell, or pleomorphic), leiomyosarcoma (non-uterine), or undifferentiated pleomorphic sarcoma
  • Have received at least one previous line of therapy
  • Have not received more than 2 lines of therapy for unresectable, locally advanced, or

    metastatic STS

Para obtener más información sobre quién puede participar en este estudio, comuníquese con el equipo del estudio al 919-681-6807.

Grupo etario
Adultos

¿Qué Implica?

If you join this study, you will get a random assignment (like drawing numbers from a hat) to either take the study drug or get a standard-of-care (SOC) treatment.

If you get the study drug, you will:

  • Get up to 5 doses of the study drug as an injection every 2 weeks
  • Continue to get doses of the study drug about every 12 weeks if you are eligible to do so after the first 5 doses

If you get a SOC treatment, you will get one of the 3 following medications that will be chosen by your doctor:

  • Pazopanib: You will take four 200 mg pills by mouth every day
  • Trabectedin: You will get an intravenous infusion (IV) every 21 days
  • Eribulin: You will get an intravenous infusion (IV) twice every 21 days

Your participation in this study is expected to last for 24 months, including follow-up checks, if necessary.

Se realizarán las siguientes pruebas y procedimientos a lo largo del estudio:

  • Exámenes físicos
  • Electrocardiograma (ECG), registro de la actividad eléctrica del corazón.
  • Blood draws and urine samples
  • Estudios de imágenes
  • Cuestionarios

Detalles del Estudio

Título Completo
A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adult Participants With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas - (THE INVINCIBLE-3 TRIAL)
Investigador Principal
Número de Protocolo
IRB: PRO00115635
NCT: NCT06263231
Fase
Phase III
ClinicalTrials.gov
Estado de inscripción
Pronto disponible para inscripción
Apoye la investigación de Duke Health o rinda homenaje a un ser querido con un regalo conmemorativo.
Contribuya a Duke Health